Serbia ALIMS Medical Device Register Analysis: 57,153 Records
A data-driven teardown of Serbia's ALIMS Register of Medical Devices: 57,153 records, EU-aligned risk classes, IVD share, country-of-origin, and authorized-representative concentration.
Serbia ALIMS Medical Device Register Teardown
For medical device manufacturers planning Southeast European market entry, Serbia is one of the larger and more under-analyzed opportunities in the Balkans. The Medicines and Medical Devices Agency of Serbia (ALIMS) maintains the national Register of Medical Devices and the companion Register of Manufacturers, and national registration remains mandatory even for devices that already carry a CE mark. That makes the register a direct read on who is actually authorized to place products on the Serbian market — and through whom.
A teardown of the ALIMS Register of Medical Devices (snapshot compiled on June 22, 2026) shows the following headline picture:
- Total Registered Records: 57,153 medical device records, each carrying a unique registry ID.
- Unique Generic Products: 5,552 unique generic device names, meaning the average generic device is registered roughly ten times across multiple authorized representatives and brand variants.
- Unique Authorized Representatives: 667 local authorized-representative entities that mediate market entry for foreign and domestic manufacturers.
- EU-Aligned Risk-Class Split: The largest single class label is Other IVD (Ostala IVD) at 13,747 records, followed by Class I at 13,311, Class IIa at 9,419, Class IIb at 5,645, and Class III at 2,937. Combined IVD-class records reach 22,456 (39.3%) of the entire register.
- Country-of-Origin Concentration: The supply chain is decisively Western. The United States leads with 11,431 records (20.0%), Germany is second with 11,357 (19.9%), and China is third with 5,998 (10.5%), followed by Italy, France, and Switzerland. The US and Germany together account for roughly 40 percent of all records.
- Authorized-Representative Concentration: The local-representative layer is moderately concentrated. MAGNA PHARMACIA DOO Belgrade leads with 3,307 records (5.8%), ahead of PROMEDIA DOO Kikinda with 1,675 (2.9%), ELTA 90 Medical Science DOO Belgrade with 1,626 (2.8%), Roche D.O.O. Belgrade with 1,503 (2.6%), and Maymedica D.O.O. Belgrade with 1,490 (2.6%). The top five authorized representatives together hold 9,601 records (16.8%).
- Leading Manufacturers: The leading individual manufacturer is Roche Diagnostics GmbH with 904 records, followed by AESCULAP AG with 887 and Siemens Healthcare Diagnostics Inc. with 829.
This teardown sizes the Serbian market, maps its EU-aligned risk-class structure, quantifies country-of-origin and local-representative concentration, and translates the data into concrete market-entry decisions. For the regional picture, it pairs with our North Macedonia MALMED medical device registry teardown and our companion Montenegro CINMED medical device register analysis.
Methodology note: This analysis is based on a compiled snapshot of the ALIMS Register of Medical Devices dated June 22, 2026. Counts are computed directly from that public register extract by MedDeviceGuide; absolute figures describe the snapshot, while proportional splits (risk class, country, representative concentration) are the more durable takeaways. The register exposes a manufacturer-country field, so country-of-origin shares are reported directly rather than inferred.
Serbia's Regulatory Framework: ALIMS and the Law on Medical Devices
ALIMS (Serbian: Agencija za lekove i medicinska sredstva) is the Serbian national authority responsible for the registration, market surveillance, and vigilance of medical devices. Founded by the Serbian Law on Medicines and Medical Devices in 2004, it succeeded earlier Yugoslav and Serbian medicines-control institutes, and today it is the competent authority a manufacturer must engage to lawfully place a device on the Serbian market.
The primary legal basis for devices is Serbia's Law on Medical Devices, supported by secondary technical regulations. Serbia is not an EU member state, but its framework is EU-aligned: the register uses the familiar MDR/IVDR-style risk-class labels (Class I, IIa, IIb, III for medical devices; List A, List B, Self-testing, and Other IVD for in-vitro diagnostics), and Serbian registration relies heavily on CE-mark documentation issued by EU Notified Bodies. Critically, however, national registration with ALIMS remains mandatory even for CE-marked devices — Serbia does not accept a CE mark alone as market authorization.
According to ALIMS, registration is filed on Form 1 with the required documentation and proof of payment, and a single application may cover multiple devices that share the same category and risk class, the same manufacturer, and the same conformity certificates. ALIMS also maintains the Register of Manufacturers, which records all foreign manufacturers (including their representative offices and branches) whose devices are registered in Serbia, alongside domestic manufacturers. In June 2025, ALIMS released updated ePortal guidance (Revision 5 for registration, Revision 3 for renewal) that consolidates submissions into a fully electronic process, sets a minimum 30-day pre-expiry window for renewals, and requires fee payment within 20 days of initiation — operational details that matter for renewal planning but do not change the underlying register structure analyzed here.
What is the volume and EU-aligned risk-class distribution of medical devices in Serbia's ALIMS register?
The ALIMS register contains 57,153 medical device records, each identified by a unique registry_id. These records map to 5,552 unique generic device names, so the average generic device type appears roughly ten times — a reflection of the same product being registered by multiple authorized representatives and across multiple brand or packaging variants. This replication is typical of hospital consumables, IVD reagents, and surgical instruments, where competing importers each secure their own registration decision.
Risk-Class Breakdown
The device_class field carries EU-aligned labels. The full distribution is:
| Risk Class (ALIMS label) | Records | Share of Register |
|---|---|---|
| Other IVD (Ostala IVD) | 13,747 | 24.0% |
| Class I | 13,311 | 23.3% |
| Class IIa | 9,419 | 16.5% |
| Class IIb | 5,645 | 9.9% |
| IVD List A (A) | 4,033 | 7.1% |
| Class III | 2,937 | 5.1% |
| IVD List C (C) | 2,067 | 3.6% |
| Class Ir | 1,777 | 3.1% |
| IVD List B (B) | 1,458 | 2.6% |
| Class Is | 1,222 | 2.1% |
| IVD List D (D) | 441 | 0.8% |
| IVD Lista B | 427 | 0.7% |
| Class Im | 273 | 0.5% |
| IVD Lista A | 231 | 0.4% |
| AIMD | 112 | 0.2% |
| IVD Self-testing (Samotestiranje) | 52 | 0.1% |
Two structural facts stand out. First, the register is IVD-heavy: when all IVD-class labels are combined (Other IVD, List A, List B, List C, List D, the Lista A and Lista B variants, and self-testing/Samotestiranje), they total 22,456 records, or 39.3% of the entire register. Serbia is a genuinely diagnostics-intensive market relative to its size. Second, the non-IVD side is weighted toward lower risk: Class I alone (13,311 records) exceeds every other non-IVD class, while Class III reaches only 2,937 records (5.1%) — a relatively small high-risk implant and active-device footprint consistent with a market of Serbia's size.
How are registered devices split between IVD and non-IVD product categories?
The register's device_category field confirms the IVD skew from a different angle and adds therapeutic context. The leading categories are:
| Product Category | Records |
|---|---|
| In Vitro Diagnostic devices (category 06) | 18,432 |
| Single-use (disposable) devices | 6,914 |
| Reusable devices | 5,164 |
| In Vitro Diagnostic devices (category W) | 3,982 |
| Dental devices | 3,646 |
| Medical equipment, accessories, software, consumables | 2,525 |
| Hospital / apparatus equipment | 2,070 |
| Devices for persons with disabilities | 2,019 |
In Vitro Diagnostics is the single largest category at 18,432 records under the primary "06" code (with an additional 3,982 under the "W" IVD code), followed by single-use devices at 6,914 and reusable devices at 5,164. The combined IVD categories therefore dominate, which is also why IVD-dedicated manufacturers — Roche, Abbott, Siemens, Beckman Coulter — appear so prominently in the manufacturer ranking below. Dental devices (3,646) and hospital apparatus (2,070) round out a category mix that is heavy on diagnostics and disposables and comparatively lighter on capital equipment.
Which manufacturer countries dominate the Serbian medical device supply chain?
Unlike some national registers that expose only a manufacturer name, the ALIMS register carries an explicit manufacturer_country field, which makes country-of-origin concentration directly measurable. The results show a decisively Western supply chain:
| Manufacturer Country (original label) | Records | Share |
|---|---|---|
| United States (Sjedinjene Američke Države) | 11,431 | 20.0% |
| Germany (Nemačka) | 11,357 | 19.9% |
| China (Kina) | 5,998 | 10.5% |
| Italy (Italija) | 4,541 | 7.9% |
| France (Francuska) | 2,526 | 4.4% |
| Switzerland (Švajcarska) | 2,450 | 4.3% |
| United Kingdom | 2,228 | 3.9% |
| Turkey (Turska) | 1,770 | 3.1% |
The United States edges out Germany by a razor-thin margin — 11,431 versus 11,357 records, a difference of 74 records — and together the two countries account for roughly 39.9 percent of the entire register. China is a distant third at 10.5%, and the next tier (Italy, France, Switzerland, the UK, Turkey) is populated almost entirely by European manufacturers. The practical reading is that Serbia's CE-reliant, EU-aligned regime favors manufacturers with established European Notified Body certificates and European distribution infrastructure; Chinese volume is concentrated heavily in lower-risk disposables and IVD reagents rather than high-risk implantables. For a US or German manufacturer, that is reassuring context: the regulatory playing field already leans toward Western brands, and competitors in your category are likely already present.
Who are the leading authorized representatives in Serbia, and how concentrated are they?
Foreign manufacturers without a Serbian establishment must register through a local authorized representative, and ALIMS records the authorized_representative_name for every device. The representative layer is the single most important commercial gatekeeper in Serbia, because the same representative often controls renewal, vigilance reporting, and tender eligibility. The top representatives are:
| Authorized Representative | Records | Share |
|---|---|---|
| MAGNA PHARMACIA DOO, Belgrade | 3,307 | 5.8% |
| PROMEDIA DOO, Kikinda | 1,675 | 2.9% |
| ELTA 90 Medical Science DOO, Belgrade – Zvezdara | 1,626 | 2.8% |
| Roche D.O.O., Belgrade | 1,503 | 2.6% |
| Maymedica D.O.O., Belgrade | 1,490 | 2.6% |
MAGNA PHARMACIA DOO Belgrade is the clear leader with 3,307 records (5.8%) — roughly double the second-ranked representative. The top five representatives together hold 9,601 records, or 16.8% of the register. By the standards of national device registers, this is moderate concentration: meaningful scale at the top, but with 667 total representatives, the long tail remains broad and there is no single dominant gatekeeper controlling a majority of the market.
Two structural observations matter for partner selection. First, several top entries are manufacturer-owned subsidiaries rather than independent distributors — Roche D.O.O. Belgrade is the local arm of Roche Diagnostics, and it appears in the top five precisely because Roche is the leading individual manufacturer (904 records). Manufacturer-owned representation reduces channel conflict but limits the representative's neutrality. Second, the independent leaders (MAGNA PHARMACIA, PROMEDIA, ELTA 90, Maymedica) are generalist representatives that handle broad portfolios across risk classes and categories, so their value depends less on category exclusivity and more on operational reliability across renewal cycles, vigilance handling, and tender support.
Which individual manufacturers lead the Serbian register?
Ranking the manufacturer_name field shows that the register's IVD intensity is reflected at the manufacturer level:
| Manufacturer | Records |
|---|---|
| Roche Diagnostics GmbH | 904 |
| AESCULAP AG | 887 |
| Siemens Healthcare Diagnostics Inc. | 829 |
| Medos International SARL | 577 |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | 487 |
Roche Diagnostics GmbH leads with 904 records — consistent with its dominance of the IVD category globally and with Roche D.O.O. Belgrade appearing among the top authorized representatives. AESCULAP AG (887) and Siemens Healthcare Diagnostics (829) follow, representing surgical instruments and diagnostics/imaging respectively. Notably, Shenzhen Mindray (487) is the leading Chinese manufacturer in the register, illustrating that Chinese presence, while third by aggregate country volume, is concentrated in specific competitive manufacturers rather than being broadly distributed.
Class III manufacturers: the high-risk competitive set
Because Class III is the most commercially sensitive tier (implants, high-risk active devices), the manufacturer ranking within that class is more decision-relevant than the overall leaderboard. Restricting the count to Class III records, the leaders are Medtronic, Inc. (201 records), Abbott Medical (148), Boston Scientific Corporation (73), implantcast GmbH (70), and Zimmer Inc. (67). This is a recognizably orthopedic-and-cardiovascular implant competitive set, and it is materially different from the IVD-led overall ranking — useful intelligence for an implant manufacturer benchmarking direct competitors rather than the whole register.
How valid is the Serbian register, and what does the renewal pipeline look like?
A register's headline size only matters if the records are active, so the decision_expiry_date field is worth examining directly. As of the June 22, 2026 snapshot, the Serbian register is unusually clean: only 884 records (1.5%) had already expired, while 56,269 records (98.5%) remained valid. Unlike some national databases that carry large volumes of legacy inactive listings, the ALIMS register is almost entirely live — which means the 57,153-record headline is a reliable read of the authorized market, not an inflated historical count.
The renewal pipeline is, however, front-loaded into a four-year window:
| Expiry Year | Records |
|---|---|
| 2029 | 15,797 |
| 2028 | 12,036 |
| 2027 | 11,442 |
| 2030 | 7,939 |
| 2026 | 6,248 |
| 2031 | 3,691 |
Roughly 6,248 records expire in 2026, with the largest cohorts falling due in 2027 (11,442), 2028 (12,036), and 2029 (15,797). For manufacturers and their authorized representatives, this is the operational planning horizon: the June 2025 ALIMS ePortal rules require renewal applications at least 30 days before expiry and fee payment within 20 days of initiation, so the 2027–2029 cohorts must be worked back from their expiry dates. The concentration of expiries in a narrow window also means authorized representatives will face peak renewal workload in those years — a factor worth raising during representative selection, since renewal bottlenecks are a leading cause of inadvertent registration lapses.
How concentrated is the authorized-representative layer, really?
The top-five share (16.8%) understates how lopsided the representative market is once you look at the full concentration curve. Across all 667 representatives:
- Just 9 representatives cover 25% of all records.
- 30 representatives cover 50% of all records.
- 101 representatives cover 75% of all records.
- 118 representatives hold 100 or more records each, while 243 representatives hold fewer than 10 records each.
In other words, half the register is mediated by only 30 firms, and the bottom 363% of the long tail (representatives with single-digit holdings) collectively controls a negligible share. The practical implication is that representative quality, not availability, is the constraint: there is no shortage of registered representatives, but the ones that materially matter — those with scale, multi-class capability, and renewal infrastructure — number in the low dozens. A manufacturer choosing among the top tier is choosing among roughly 30 credible partners, not 667.
Strategic Implications for Market Entry
The data supports four concrete decisions for manufacturers evaluating Serbia:
- Treat Serbia as a CE-acceptance beachhead, not a greenfield market. With 57,153 records under an EU-aligned class structure and a register that is 39.3% IVD, the market is already densely populated by US and German brands. Realistic entry planning should assume competitors are present in your category and budget for differentiation, not for category creation.
- Select an authorized representative on regulatory capability, not headcount. The representative layer is only moderately concentrated (top five at 16.8%), so manufacturers have genuine choice. Prioritize representatives with proven MDR/IVDR-aligned class-handling capability, renewal discipline (the 30-day pre-expiry ePortal window is unforgiving), and vigilance infrastructure over raw registration count.
- Plan around the ePortal renewal cycle. The June 2025 move to fully electronic ALIMS ePortal submissions means renewal timing, fee payment within 20 days, and bundled-application restrictions (same class, category, and certificate) are now operational constraints. Build these into your regulatory calendar from the first registration.
- IVD manufacturers face a more crowded entry than implant makers. Because IVD is 39.3% of the register and Roche, Siemens, and Abbott are deeply entrenched, IVD entrants should expect intense competition for distributor and tender access. Class III implant and active-device entrants face a smaller (2,937-record) but less crowded field.
How does Serbia compare to its Western Balkan neighbors?
Placing Serbia alongside its Balkan peers clarifies where it sits in a regional filing sequence. Serbia's ALIMS register, at 57,153 records, is roughly 11 times the size of North Macedonia's MALMED register (5,223 records) and about 3.8 times the size of Montenegro's CINMED register (15,179 records), making it by far the largest of the three EU-aligned Western Balkan markets analyzed here. All three share a CE-reliant, MDR/IVDR-aligned class structure and a mandatory national registration step, so the documentary effort per market is broadly comparable — but the commercial payoff scales with register size, which favors sequencing Serbia first or early in a Balkan rollout.
The three markets also differ structurally in ways that affect partner strategy. Serbia is moderately concentrated (top five representatives at 16.8%), whereas Montenegro is exceptionally concentrated (top five holders at 50.4%) and North Macedonia sits between them (top five at roughly 30%). Serbia is also the only one of the three whose public register exposes a manufacturer-country field, which is why this teardown can report US and German dominance (about 40% of records combined) directly. The IVD intensity rises as the markets get smaller: IVD classes are 39.3% of Serbia, but over half of Montenegro. For a manufacturer, the implication is that a single regional representative strategy is rarely optimal — concentration profiles differ enough that partner diligence should be market-specific, even when the underlying CE documentation is shared.
Frequently Asked Questions
What regulator maintains the Register of Medical Devices in Serbia?
The Medicines and Medical Devices Agency of Serbia (ALIMS) maintains both the Register of Medical Devices and the Register of Manufacturers. National registration with ALIMS is mandatory, including for devices that already carry a CE mark.
Does a CE mark allow immediate market access in Serbia?
No. Serbia is not an EU member state, and while its framework is EU-aligned and relies heavily on CE-mark and Notified Body documentation, manufacturers must still complete national ALIMS registration and be listed in the register before placing a device on the Serbian market.
Which authorized representative holds the largest share of Serbian ALIMS medical device registrations?
MAGNA PHARMACIA DOO Belgrade leads with 3,307 records (5.8% of the register). The top five authorized representatives together hold 9,601 records (16.8%), indicating moderate rather than extreme concentration.
How IVD-heavy is the Serbian medical device register?
Combined IVD-class records total 22,456, or 39.3% of all 57,153 records. Other IVD (Ostala IVD) at 13,747 records is the single largest risk-class label in the entire register.
Do registration counts in the ALIMS register reflect market share?
Not directly. Counts reflect registered product records, not unit sales, and the same generic device is often registered multiple times by different representatives. Country-of-origin and representative shares are reliable for competitive structure; revenue share requires separate commercial data.
How clean is the ALIMS register?
Very clean. As of the June 22, 2026 snapshot, only about 1.5% of records (884 of 57,153) had expired, so the headline count is a reliable read of the active authorized market rather than an inflated historical figure.
Can one authorized representative cover multiple device classes and categories?
Yes. A single ALIMS application may cover multiple devices that share the same category and risk class, the same manufacturer, and the same conformity certificates, and large generalist representatives (such as MAGNA PHARMACIA, PROMEDIA, and ELTA 90) actively manage portfolios spanning several classes and categories.
Conclusion
Serbia's ALIMS register reveals a sizable, EU-aligned, and IVD-intensive medical device market of 57,153 records, dominated by US and German manufacturers and mediated by a moderately concentrated layer of 667 authorized representatives. For foreign manufacturers, the actionable insight is partner selection: the regulatory playing field already favors Western brands with CE documentation, so the binding decision is choosing a representative with the MDR/IVDR class-handling capability and renewal discipline to sustain registration across cycles — not whether to enter, but through whom.
This article is educational and is not legal, regulatory, or commercial advice for any specific product or company. Registration requirements change; verify current requirements directly with ALIMS before acting.
Sources
- ALIMS — Registration in the Register of Medical Devices (official): Medicines and Medical Devices Agency of Serbia,
alims.gov.rs/english/medical-devices/registration-in-the-register-of-medical-devices. - ALIMS — official agency site (official): Medicines and Medical Devices Agency of Serbia,
alims.gov.rs/english/. - Medicines and Medical Devices Agency of Serbia (reference): Wikipedia summary of ALIMS, founded 2004 under the Serbian Law on Medicines and Medical Devices.
- Serbia Medical Device Registration and ALIMS Compliance (consultancy): Proregulations,
proregulations.com. - Serbia Medical Device Registration overview (consultancy): OMC Medical,
omcmedical.com. - ALIMS ePortal digitalization (June 30, 2025) (industry): regulatory-affairs reporting on ALIMS Revision 5 registration and Revision 3 renewal guidance.
- Register data (dataset): MedDeviceGuide analysis of the ALIMS Register of Medical Devices public extract, snapshot dated June 22, 2026.